Abstract
Background Exposures to stress and traumatic events plays a significant role in triggering or precipitating anxiety. Nonetheless, these are often examined at the individual level, while societal-environmental exposures and their association with anxiety disorders are under-researched, especially in the Israeli context. This study leverages 19 years of longitudinal data from a large healthcare organization to examine the impact of national security instability on short-term anxiolytic purchases in Israel.
Methods We conducted a retrospective cohort study using electronic medical records of over 1.1 million individuals from 2006 to 2024, examining rates of first-time and renewed use of anxiolytic medications of the benzodiazepines group during periods of armed conflict, including military operations and wars. Cox proportional hazards models were used to assess associations, adjusting for confounders such as age, sex, socioeconomic status, socioreligious sector, residence and previous psychiatric treatment.
Results The risk for first purchase of an anxiety-relief short terms medication during military operations was 28% higher (HR 1.28, 95% CI: 1.21-1.34) compared to periods of relative national stability, after adjustments, and 44% higher during the Second Lebanon War (HR 1.44, 95% CI 1.27-1.62). The events of October 7th were the most significant armed conflict increasing the risk for anxiety-related reaction necessitating treatment throughout the 19-years follow-up, with individuals at 317% increased risk for treatment initiation compared to periods of relative national stability (HR 4.17, 95% CI 3.97-4.38). Alongside a baseline increased risk for initiating anti-anxiety treatment, women experienced an additional elevated risk for anxiolytic therapy during times of national security threats, with 26% additional increased risk during military operations and an 81% increased risk following the events of October 7th. Residents of northern Israel had an increased risk of purchasing anxiolytics during the Second Lebanon War (HR 1.39, 95% CI: 1.12-1.72), while during military operations it was the residents of southern Israel who faced an increased risk for anxiolytic usage, with an HR of 1.18 (95% CI: 1.05-1.33). Conversely, the residential region did not significantly influence anti-anxiety treatment patterns following October 7th among residents of southern or northern Israel, compared to individuals living in central Israel, indicating a broader national impact beyond regional differences.
Conclusions National armed conflicts significantly influence anxiolytic medication use in Israel, with the October 7th war showing the most pronounced effect. These findings highlight the need for comprehensive mental health interventions during times of national crisis, focusing on both short-term relief and long-term mental health support to prevent dependency and improve mental health outcomes in the wake of national crises.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no external funding for the project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Maccabi Healthcare Services Institutional Review Board (protocol number 0097-23-MHS). Due to the retrospective design of the study, informed consent was waived by the IRB, and all identifying details of the participants were removed before analysis.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
According to the Israel Ministry of Health regulations, individual-level data cannot be shared openly. Specific requests for remote access to de-identified community-level data or code used should be referred to Maccabi Healthcare Services Research and Innovation Center.
